A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well

International Journal of Cancer

Volumn 126, Issue 2, 2010, Pages 483-489

  Lyytinen, Heli K ^a   Dyba, Tadeusz ^b   Ylikorkala, Olavi ^a   Pukkala, Eero I ^b,c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b FINNISH CANCER REGISTRY   (Finland)

^c UNIVERSITY OF TAMPERE   (Finland)

Author keywords

Breast cancer; Estrogen; Hormone therapy; Medicated intrauterine system; Postmenopause; Progestagen

Indexed keywords

DROSPIRENONE; DYDROGESTERONE; ESTRADIOL; GESTAGEN; LEVONORGESTREL; LYNESTRENOL; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NORETHISTERONE ACETATE; PROGESTERONE; TIBOLONE; TRIMEGESTONE;

ADULT; ARTICLE; BREAST CANCER; CANCER REGISTRY; CANCER RISK; CONTROLLED STUDY; FEMALE; FINLAND; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FINLAND; HUMANS; INTRAUTERINE DEVICES, MEDICATED; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; PROGESTINS; RISK FACTORS;

EID: 73549107866     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24738     Document Type: Article

References (28)

1. Collins JA, Blake JM, Crosignani PG. Breast cancer risk with postmenopausal hormone treatment. Hum Reprod Update 2005;111:545-60.
2. Lee SA, Ross RK, Pike MC. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 2005;92:2049-58.
3. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006;108:1354-60.
4. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using oestradiol-progestagen therapy. Obstet Gynecol 2009;113:65-73.
5. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994;33:365-69.
6. Sincich T. Statistics by example, 3rd edn., San Francisco: Dellen, 1987.
7. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103-11.
8. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001;2:133-40.
9. Pukkala E, Weiderpass E. Time trends in socio-economic differences in incidence rates of cancers of the breast and female genital organs (Finland, 1971-1995). Int J Cancer 1999;81:56-61.
10. Pukkala E, Patama T, Engholm G, Ólafsdóttir GH, Bray F, Talbäck M, Pasanen K. Small-area based map animations of cancer incidence in the Nordic countries, 1971-2003, Nordic Cancer Union, 2007. Available at: http://astra.cancer.fi/cancermaps/Nordic. Accessed December 14, 2008.
11. Topo P, Luoto R, Hemminki E, Uutela A. Declining socioeconomic differences in the use of menopausal and postmenopausal hormone therapy in Finland. Maturitas 1999;32:141-45.
12. Cuzick J. Epidemiology of breast cancer - selected highlights. Breast 2003;12:405-11.
13. Sarkeala T, Heinävaara S, Anttila A. Organised mammography screening reduces breast cancer mortality: a cohort study from Finland. Int J Cancer 2008;122:614-19.
14. Olsson HL, Ingvar C, Bladstrom A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003;97:1387-92.
15. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
16. Beral V. Million Women Study C. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
17. Porch JV, Lee IM, Cook NR, Rexrode KM, Burin JE. Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control 2002;13:847-48.
18. Jernstöm H, Bendahl P-O, Lidfeldt J, Nerbrand C, Agardh C-D, Samsioe G. A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women's health in the Lund area (WHILA) study (Sweden). Cancer Causes Control 2003;14:673-80.
19. Bakken K, Alsaker E, Eggen AE, Lund E. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian women and cancer study. Int J Cancer 2004;112:130-34.
20. Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Berger J, Chang-Claude J. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 2008;123:933-41.
21. Stahlberg C, Pedersen AT, Lynge E, Andersen ZJ, Keiding N, Hundrup YA, Obel EB, Ottesen B. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 2004;109:721-27.
22. Kenemans P, Bundred NJ, Foidart JM, Kubista E, Von Schoultz B, Sismondi P, Vassipoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, Van Os S, et al. LIBERATE Study Group. Lancet Oncol 2009;10:135-46.
23. Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697-708.
24. Backman T, Rauramo I, Jaakkola K, Inki P, Vaahtera K, Launonen A, Koskenvuo M. Use of levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 2005;106:813-17.
25. Horwitz KB, Sartorius CA. Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab 2008;93:3295-98.
26. Raudaskoski T, Tapanainen J, Tomas E, Luotola H, Pekonen F, Ronni-Sivula H, Timonen H, Riphagen F, Laatikainen T. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG 2002;109:136-44.
27. Backman T, Huhtala S, Luoto R, Tuominen J, Rauramo I, Koskenvuo M. Advance information improves user satisfaction with the levonorgestrel intrauterine system. Obstet Gynecol 2002;99:608-13.
28. Jensen JT, Nelson AL, Costales AC. Subject and clinician experience with the levonorgestrel-releasing intrauterine system. Contraception 2008;77:22-2.